Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) CTO Metin Kurtoglu sold 25,900 shares of the company's stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $16.44, for a total transaction of $425,796.00. Following the completion of the transaction, the chief technology officer now owns 51,033 shares of the company's stock, valued at approximately $838,982.52. The trade was a 33.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Metin Kurtoglu also recently made the following trade(s):
- On Monday, November 18th, Metin Kurtoglu sold 34,400 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $18.39, for a total transaction of $632,616.00.
Cartesian Therapeutics Trading Up 7.2 %
Shares of RNAC stock opened at $18.57 on Tuesday. The stock has a market capitalization of $471.96 million, a price-to-earnings ratio of -0.35 and a beta of 0.63. Cartesian Therapeutics, Inc. has a 12-month low of $11.66 and a 12-month high of $42.60. The stock's 50-day moving average price is $19.26 and its 200-day moving average price is $20.23.
Institutional Trading of Cartesian Therapeutics
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
A number of large investors have recently added to or reduced their stakes in the company. Artal Group S.A. bought a new position in shares of Cartesian Therapeutics during the 1st quarter valued at approximately $5,939,000. Vanguard Group Inc. bought a new stake in Cartesian Therapeutics in the first quarter worth $4,105,000. FMR LLC raised its stake in Cartesian Therapeutics by 458.3% during the third quarter. FMR LLC now owns 2,851,830 shares of the company's stock valued at $45,972,000 after purchasing an additional 2,341,054 shares in the last quarter. Great Point Partners LLC bought a new position in Cartesian Therapeutics during the third quarter valued at $3,224,000. Finally, State Street Corp grew its stake in shares of Cartesian Therapeutics by 2.5% in the 3rd quarter. State Street Corp now owns 157,495 shares of the company's stock worth $2,539,000 after buying an additional 3,830 shares in the last quarter. Institutional investors own 86.95% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. TD Cowen assumed coverage on Cartesian Therapeutics in a report on Tuesday, August 6th. They set a "buy" rating on the stock. HC Wainwright decreased their target price on Cartesian Therapeutics from $45.00 to $41.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $41.00 price target on shares of Cartesian Therapeutics in a research note on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $42.33.
View Our Latest Analysis on RNAC
About Cartesian Therapeutics
(
Get Free Report)
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
